These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 93216)

  • 1. Effects of piracetam and iodoacetamide on erythrocyte sickling.
    Costa FF; Zago MA; Bottura C
    Lancet; 1979 Dec; 2(8155):1302. PubMed ID: 93216
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of piracetam on sickle erythrocytes and sickle hemoglobin.
    Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Devlin MT; Schwartz E
    Biochim Biophys Acta; 1981 May; 668(3):397-405. PubMed ID: 7236716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piracetam and acetamide in sickle-cell disease.
    de Araujo JT; Nero GS
    Lancet; 1977 Aug; 2(8034):411. PubMed ID: 70630
    [No Abstract]   [Full Text] [Related]  

  • 4. Sickle-cell disease: Two new therapeutic strategies.
    Nalbandian RM; Henry RL; Murayama M
    Lancet; 1978 Sep; 2(8089):570-1. PubMed ID: 79930
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro inhibition of the rate of erythrocyte sickling by RMI 11,071A and its possible mechanism.
    MacKenzie RD; Gleason EM; Schatzman GL; Cawein MJ
    Proc Soc Exp Biol Med; 1979 Oct; 162(1):224-6. PubMed ID: 504233
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythrocyte - endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: adverse effects reversed with piracetam.
    Nalbandian RM; Henry RL; Fleischman JA; Burek L; Williams G; O'Donnell FE; Diglio CA; Collier BD; Reeser FH
    Med Hypotheses; 1982 Feb; 8(2):155-62. PubMed ID: 7045599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of piracetam improves sickle cell deformability in vitro and in vivo.
    Gini EK; Sonnet J
    J Clin Pathol; 1987 Jan; 40(1):99-102. PubMed ID: 3818978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam.
    Nalbandian RM; Henry RL; Burek CL; Diglio CA; Goldman AI; Taylor GW; Hoffman WH
    Am J Hematol; 1983 Sep; 15(2):147-51. PubMed ID: 6613985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piracetam and sickle-cell disease.
    Franklin IM
    Lancet; 1980 Apr; 1(8171):767-8. PubMed ID: 6103182
    [No Abstract]   [Full Text] [Related]  

  • 10. Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased intracellular hemoglobin concentration and decreased in vitro sickling without prolonged in vivo survival.
    Franco R; Barker-Gear R; Silberstein E; Mayfield G; Weiner M; Palascak J; Green R
    Adv Exp Med Biol; 1992; 326():325-31. PubMed ID: 1295319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sulfhydryl reagents on the anti-sickling activity of some membrane-interacting compounds.
    Sato T; Ohnishi ST
    Biochim Biophys Acta; 1983 Jan; 727(1):196-200. PubMed ID: 6824650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular basis of antisickling agents.
    Franklin IM; Huehns ER
    Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123
    [No Abstract]   [Full Text] [Related]  

  • 13. Viscosity and filtrability measurements of sickle-cell suspensions in the development of anti-sickling drugs.
    Ohnishi ST
    Blood Cells; 1982; 8(1):79-87. PubMed ID: 7115980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisickling effects of membrane-interacting compounds.
    Ohnishi ST
    Blood Cells; 1982; 8(2):337-43. PubMed ID: 6130805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piracetam in sickle-cell anaemia.
    de Melo GO
    Lancet; 1976 Nov; 2(7995):1139-40. PubMed ID: 62977
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
    Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Trial prevention of vaso-occlusive crises in homozygote sickle cell anemia using piracetam].
    Sonnet J; Gini EK; Cornu G
    Ann Soc Belg Med Trop; 1985; 65(1):77-84. PubMed ID: 4004377
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibitors of sickling.
    Mentzer WC
    Am J Pediatr Hematol Oncol; 1982; 4(3):320-7. PubMed ID: 7149171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane modifiers in sickle cell disease.
    Benjamin LJ
    Ann N Y Acad Sci; 1989; 565():247-61. PubMed ID: 2672964
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of pH on the rheologic and antisickling effects of dimethyl adipimidate.
    Pennathur-Das R; Lande WM; Mentzer WC; Mohandas N; Preisler H; Kleman KM; Heath RH; Lubin BH
    J Lab Clin Med; 1984 Nov; 104(5):718-29. PubMed ID: 6491469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.